Complementary Therapies for Parkinson's Disease: What's Promoted, Rationale, Potential Risks and Benefits

Rabin, Marcie L.; Stevens-Haas, Claire; Havrilla, Emilyrose; Rosenstein, Adam; Toffey, Brittany; Devi, Tanvi; Earnhardt, Mary Cathryn; Kurlan, Roger

doi:10.1002/mdc3.12170

Cited by 8 publications

(7 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recent MDS systematic review concluded that, in PD-MCI, the monoamine oxidase B (MAO-B) inhibitors rasagiline and rivastigmine presented an acceptable risk of adverse events, without specialized monitoring, but there is still insufficient evidence on their efficacy [ 44 ]. Non-pharmacological interventions, including transcranial direct-current stimulation (T-DCS) and cognitive rehabilitation are still under investigation [ 44 , 45 ].…”

Section: Introductionmentioning

confidence: 99%

Parkinson’s Disease-Cognitive Rating Scale for Evaluating Cognitive Impairment in Parkinson’s Disease: A Systematic Review

Roşca

Simu

2020

Brain Sciences

View full text Add to dashboard Cite

The aim of the present systematic review was to examine the evidence on the accuracy and psychometric properties of the Parkinson’s Disease-Cognitive Rating Scale (PD-CRS) for evaluating the presence of cognitive impairment in patients with Parkinson’s disease (PD) as well as to highlight the quality and quantity of research available on the use of the PD-CRS in this population. We searched four databases from inception until July 2020. Eight studies, published between 2008 and 2020, met the inclusion criteria: One cross-sectional study in which participants were assessed with the index test (PD-CRS) and a reference standard diagnostic assessment, in accordance with the Level II criteria of the International Parkinson and Movement Disorder Society (MDS); one case-control study comparing the PD-CRS to an extensive battery of tests (i.e., MDS Level II diagnosis); and six studies comparing the PD-CRS to other short cognitive batteries. In patients with Parkinson’s disease, the PD-CRS test provides information about cortical and sub-cortical cognitive functions. Even if it demonstrated good psychometric properties, the results regarding the optimal threshold for detecting mild cognitive impairment and dementia in PD are somewhat inconsistent. Further cross-sectional studies are necessary to examine the optimum cut-off score for detecting cognitive dysfunction in PD patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Parkinson’s Disease-Cognitive Rating Scale for Evaluating Cognitive Impairment in Parkinson’s Disease: A Systematic Review

Roşca

Simu

2020

Brain Sciences

View full text Add to dashboard Cite

show abstract

“…Vitamins such as beta-carotenes or vitamin B6 also have antioxidant properties, and evidence from two case-control studies shows that they decrease the risk for PD [69,70]. Unsaturated fatty acids and other plant-derived micronutrients reduce proinflammatory cytokine production and may reduce inflammation in these patients [71]. In conclusion, the pro-dopaminergic effect of AtreMorine can be attributed to the rich content of natural L-DOPA (average concentration 20 mg/g) in its composition.…”

Section: Discussionmentioning

confidence: 95%

Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals

et al. 2020

View full text Add to dashboard Cite

The investigation of new alternatives for disease prevention through the application of findings from dietary and food biotechnology is an ongoing challenge for the scientific community. New nutritional trends and the need to meet social and health demands have inspired the concept of functional foods and nutraceuticals which, in addition to their overall nutritional value, present certain properties for the maintenance of health. However, these effects are not universal. Nutrigenetics describes how the genetic profile has an impact on the response of the body to bioactive food components by influencing their absorption, metabolism, and site of action. The EbioSea Program, for biomarine prospection, and the Blue Butterfly Program, for the screening of vegetable-derived bioproducts, have identified a new series of nutraceuticals, devoid of side effects at conventional doses, with genotype-dependent preventive and therapeutic activity. Nutrigenomics and nutrigenetics provide the opportunity to explore the inter-individual differences in the metabolism of and response to nutrients, achieving optimal results. This fact leads to the concept of personalized nutrition as opposed to public health nutrition. Consequently, the development and prescription of nutraceuticals according to the individual genetic profile is essential to improve their effectiveness in the prevention and natural treatment of prevalent diseases.

show abstract

“…Our search was limited to articles published between 1982 and 2022. Subsequently, we cross-checked our findings with findings reported in some of the most recently published comprehensive reviews on pharmacological treatments or food supplements targeting mitochondrial dysfunction in PD [10,[17][18][19][20][21]. The list of compounds identified is available in Table 1.…”

Section: Methodsmentioning

confidence: 97%

Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson’s Disease Patients

Ciocca

Pizzamiglio²

2024

CNSNDDT

View full text Add to dashboard Cite

Parkinson’s disease is the second most common neurodegenerative disease. Mitochondrial dysfunction has been associated with neurodegeneration in Parkinson’s disease, and several treatments targeting mitochondria have been tested in these patients to delay disease progression and tackle disease symptoms. Herein, we review available data from randomised, double-blind clinical studies that have investigated the role of compounds targeting mitochondria in idiopathic Parkinson’s disease patients, with a view of providing patients and clinicians with a comprehensive and practical paper that can inform therapeutic interventions in this group of people. A total of 9 compounds have been tested in randomized clinical trials, but only exenatide has shown some promising neuroprotective and symptomatic effects. However, whether this evidence can be translated into daily clinical practice still needs to be confirmed. In conclusion, targeting mitochondrial dysfunction in Parkinson’s disease is a promising therapeutic approach, although only one compound has shown a positive effect on Parkinson’s disease progression and symptoms. New compounds have been investigated in animal models, and their efficacy needs to be confirmed in humans through robust, randomised, double-blind clinical trials.

show abstract

Complementary Therapies for Parkinson's Disease: What's Promoted, Rationale, Potential Risks and Benefits

Cited by 8 publications

References 55 publications

Parkinson’s Disease-Cognitive Rating Scale for Evaluating Cognitive Impairment in Parkinson’s Disease: A Systematic Review

Parkinson’s Disease-Cognitive Rating Scale for Evaluating Cognitive Impairment in Parkinson’s Disease: A Systematic Review

Nutrition, Health, and Disease: Role of Selected Marine and Vegetal Nutraceuticals

Clinical Benefits of Therapeutic Interventions Targeting Mitochondria in Parkinson’s Disease Patients

Contact Info

Product

Resources

About